Evkeeza الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

evkeeza

ultragenyx germany gmbh - evinacumab - kólesterólhækkun - lipid breytandi lyf - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Nebido Stungulyf, lausn 1000 mg/ 4 ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

nebido stungulyf, lausn 1000 mg/ 4 ml

grünenthal gmbh* - testosterone - stungulyf, lausn - 1000 mg/ 4 ml

Livopan Lyfjagas undir þrýstingi 50/50 % أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

livopan lyfjagas undir þrýstingi 50/50 %

linde sverige ab - dinitrogenii oxidum; oxygenium - lyfjagas undir þrýstingi - 50/50 %

Gentamicin B. Braun Innrennslislyf, lausn 1 mg/ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

gentamicin b. braun innrennslislyf, lausn 1 mg/ml

b. braun melsungen ag - gentamicinum súlfat - innrennslislyf, lausn - 1 mg/ml

Gentamicin B. Braun Innrennslislyf, lausn 3 mg/ml أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

gentamicin b. braun innrennslislyf, lausn 3 mg/ml

b. braun melsungen ag - gentamicinum súlfat - innrennslislyf, lausn - 3 mg/ml

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 10 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 10 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 10 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 20 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 20 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 20 mg

Sandostatin LAR Stungulyfsstofn og leysir, dreifa 30 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sandostatin lar stungulyfsstofn og leysir, dreifa 30 mg

novartis healthcare a/s - octreotidum inn - stungulyfsstofn og leysir, dreifa - 30 mg

Sinemet Depot Mite (Sinemet depot mite) Forðatafla 25 mg/100 mg أيسلندا - الأيسلاندية - LYFJASTOFNUN (Icelandic Medicines Agency)

sinemet depot mite (sinemet depot mite) forðatafla 25 mg/100 mg

n.v. organon* - levodopum inn; carbidopum inn - forðatafla - 25 mg/100 mg

Advate الاتحاد الأوروبي - الأيسلاندية - EMA (European Medicines Agency)

advate

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorrhagics - meðferð og fyrirbyggjandi blæðingar hjá sjúklingum með dreyrasýki a (meðfæddan þáttur viii-skortur). advate inniheldur ekki von willebrand þáttur í ly árangri magni og er því ekki fram í von willebrand sjúkdómur.